Assessing Adverse Drug Reactions and Safety Profiles of COVID-19 Drug Combinations: A Data-Driven Analysis with Emphasis on Vulnerable Populations
Mona Ahmed Ibrahim Abdelhalim
Department of Medicine, Luxor University, Luxor, Egypt
Waseem Ahmed Khattak
Quaid-I-Azam University Islamabad, Pakistan Department of Plant Sciences
Keywords: COVID-19, Drug Combinations, Adverse Reactions, Safety Profiles, Vulnerable Populations, Epidemiology, Treatment Approaches
Abstract
The COVID-19 pandemic has necessitated the rapid development and deployment of drug combinations as potential therapeutic strategies. These combinations, while holding promise for enhanced efficacy, bring forth the crucial imperative of assessing their safety profiles, particularly with regard to adverse drug reactions (ADRs), and understanding their impact on vulnerable populations. This data-driven analysis aims to comprehensively evaluate the ADRs and safety profiles of COVID-19 drug combinations, emphasizing the unique vulnerabilities of certain patient groups. Through a systematic review of pharmaceutical databases, clinical trial data, and real-world evidence, we assess the frequency, severity, and clinical implications of ADRs associated with these regimens. We also perform comparative analyses to elucidate differences in safety profiles between various combinations. Furthermore, we place special emphasis on vulnerable populations, including the elderly and immunocompromised individuals, by conducting subgroup analyses to tailor insights and recommendations to their specific needs. Our findings reveal a nuanced safety landscape, highlighting both known and previously unrecognized ADRs, thus enhancing our understanding of the risks and benefits associated with COVID-19 drug combinations. The importance of this research lies in its potential to inform clinical practice, guide treatment decisions, and contribute to the ongoing global effort to combat the pandemic effectively while ensuring patient safety, particularly among those who are most vulnerable. By addressing the critical aspects of drug safety in the context of COVID-19 treatment, this study aims to optimize therapeutic outcomes and promote health equity.
